アメリカ アメリカ

証券取引委員会

ワシントンD.C.，20549

表 8-K

現在 報告

条約第十三項又は十五(D)節によれば

1934年証券取引法

報告日 (最初のイベント報告日)：2023年2月7日

Aesther医療買収会社

(登録者の正確な名称は、その定款に規定されている名称と同じ)

(646) 908-2659

(登録者の電話番号、市外局番を含む)

適用されない

(前 名前または前の住所、前回の報告から変更された場合)

表8-Kが登録者が以下のいずれかに規定する届出義務を同時に満たすことを意図している場合、次の対応する枠を選択してください

同法第12条(B)に基づいて登録された証券：

第 9.01項.財務諸表と証拠品です。

展示品です。

添付ファイル 番号：

説明する

表紙 ページ相互データファイル(イントラネットXBRL埋め込み)サイン

1934年の証券取引法の要求に基づき、登録者は、以下の署名者がその代表として本報告書に署名することを正式に許可した。

AESTHER ヘルスケア買収会社。

差出人：

/s/ Suren Ajjarapu

名前：

蘇仁 アギラップ

タイトル：

CEO

日付： 2023年2月7日SEC”) a Definitive Proxy Statement on Schedule 14A relating to the proposed transaction. This communication is not intended to be, and is not, a substitute for the Definitive Proxy Statement or any other document that Aesther has filed or may file with the SEC in connection with the proposed transaction. Aesther’s stockholders and other interested persons are advised to read the Definitive Proxy Statement and the amendments thereto, and documents incorporated by reference therein filed in connection with the proposed transaction, as these materials will contain important information about Aesther, Ocean Biomedical, the Merger Agreement, and the proposed transaction. The Definitive Proxy Statement and other relevant materials for the proposed transaction will be mailed to stockholders of Aesther as of a record date to be established for voting on the proposed transaction. Before making any voting or investment decision, investors and stockholders of Aesther are urged to carefully read the entire Definitive Proxy Statement and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. Aesther investors and stockholders will also be able to obtain copies of the Definitive Proxy Statement and other documents filed with the SEC that will be incorporated by reference therein, without charge, at the SEC’s website at www.sec.gov, or by directing a request to: Aesther Healthcare Acquisition Corp., 515 Madison Avenue, Suite 8078, New York, NY 10022, Attention: Mr. Suren Ajjarapu.

Participants in the Solicitation

Aesther, Ocean Biomedical and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Aesther’s stockholders with respect to the proposed transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of Aesther’s directors and officers in Aesther’s filings with the SEC, including its most recent Annual Report on Form 10-K, the Definitive Proxy Statement, and other documents filed with the SEC.

No Offer or Solicitation

This filing is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 7, 2023